Denali Therapeutics, which is developing treatments for neurodegenerative diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The San Francisco, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol DNLI. Denali Therapeutics filed confidentially on September 8, 2017. Goldman Sachs, Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.
